Easterly Investment Partners LLC boosted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 27.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,025 shares of the company's stock after purchasing an additional 25,211 shares during the quarter. Johnson & Johnson comprises 1.6% of Easterly Investment Partners LLC's investment portfolio, making the stock its 11th biggest position. Easterly Investment Partners LLC's holdings in Johnson & Johnson were worth $19,407,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. WealthTrak Capital Management LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $29,000. Conquis Financial LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $33,000. Bernard Wealth Management Corp. purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $36,000. Finally, Highline Wealth Partners LLC raised its position in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several research firms have recently weighed in on JNJ. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Royal Bank Of Canada raised their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research report on Thursday. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday. Bank of America increased their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday. Finally, Guggenheim increased their target price on shares of Johnson & Johnson from $164.00 to $167.00 and gave the company a "neutral" rating in a report on Thursday. Eleven investment analysts have rated the stock with a hold rating, nine have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average target price of $174.11.
View Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Trading Up 0.4%
Johnson & Johnson stock traded up $0.67 during trading hours on Friday, reaching $163.65. The stock had a trading volume of 9,764,459 shares, compared to its average volume of 8,138,164. The company has a fifty day simple moving average of $154.10 and a 200-day simple moving average of $154.84. The stock has a market cap of $393.75 billion, a PE ratio of 17.50, a PEG ratio of 2.18 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The company's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.82 EPS. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.
Johnson & Johnson Company Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Recommended Stories
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
